Funding Gap For Life Science Cos. Is Still A Problem

Law360, New York (September 5, 2013, 12:16 PM EDT) -- During the first half of 2013, midstage life sciences companies have seen more initial public offerings than any year since 2004. However, for startup life sciences companies, the capital markets are decidedly less optimistic. Before these young companies can take advantage of a hot IPO market, they must raise substantial sums of money for research and development, intellectual property protection and clinical trials.

In fact, the typical drug or device company completing a successful IPO in the first half of 2013 raised approximately $100 million through...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.